In March, mbiomics GmbH, a Munich based biotech company developing microbiome-based therapeutics announced the first closing of 13 Mio. €of a series A financing round led by MIG Capital. High-Tech Gründerfonds (HTGF) and Bayern Kapital joined the funding round together with a pool of private seed investors.

mbiomics was founded in 2020 and is a privately held biotech company, with a focus on developing the first generation of effective live bacterial therapeutics (LBT). The company is leveraging its tailored microbiome diagnostic platform to overcome current bottlenecks in LBT development – by generating precision profiling data, selecting better informed consortia, improving patient stratification and patient monitoring for clinical trials.

With the announced closing, mbiomics is in a position to spearhead the emerging field of synthetic microbial consortia with the potential to revolutionize the treatment of a wide range of diseases, from cancer to inflammatory bowel diseases.

“We are thrilled to have the support of such a strong group of investors who share our vision of using the power of the gut microbiome to develop targeted therapies,” said Dr. Laura Figulla, co-founder and CEO of mbiomics. “This funding will enable us to build our platform, accelerate the identification of our first lead drug candidates, and speed up the research efforts towards clinical validation.”

mbiomics will use the proceeds to embark on strategic partnerships, significantly expand their Munich laboratory facilities and R&D teams in Germany, and potentially increase US activities.